
    
      This is a double-blind (neither study staff or the patient will know the identity of the
      treatment assigned) study of canagliflozin in patients with Type 2 Diabetes Mellitus (T2DM)
      who are currently taking metformin at a stable dose of >=1500 mg/day. Patients will
      participate in the study for up to approximately 16 weeks. During the study, patients will
      receive 4 treatments (A, B, C, and D); each treatment will be administered during a 3-day
      treatment period. Patients will receive 1 dose of study medication in the morning of Day 1
      and Day 2 of each treatment period and treatment periods will be separated by approximately 2
      weeks. Treatments will consist of placebo (A), canagliflozin 300 mg and placebo (B),
      canagliflozin 300mg (C), and canagliflozin 300mg and canagliflozin 150mg (D).
    
  